Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy.

Abstract

BACKGROUND:

  A hypoallergen of the major cat allergen Fel d 1, recombinant (r) Fel d 1 (DTE III), was previously shown to have retained T-cell reactivity and strongly reduced IgE-binding capacity compared to unmodified rFel d 1. Here, we evaluated the therapeutic capacity of rFel d 1 (DTE III) in a mouse model for cat allergy.

METHODS:

  Mice were subcutaneously (s.c.) sensitized with rFel d 1 and subsequently treated (s.c.) with 50 or 200 μg rFel d 1 (DTE III), or 50 μg rFel d 1, prior to intranasal challenge with cat dander extract. Airway hyperreactivity (AHR), cells and cytokines in bronchoalveolar lavage fluid, splenocyte in vitro response, and serum immunoglobulins were analyzed. Seven cat-allergic patients and ten healthy controls were tested for skin prick test (SPT) reactivity to rFel d 1 (DTE III) and rFel d 1.

RESULTS:

  Mice treated with 50 and 200 μg rFel d 1 (DTE III), and 50 μg rFel d 1, produced increased serum levels of rFel d 1-specific IgG1 and IgG2a compared to sham-treated mice. IgG from all treatment groups could block binding of patients' IgE to rFel d 1. The 200 μg rFel d 1 (DTE III) treatment tended to reduce AHR. All mice tolerated treatment with rFel d 1 (DTE III), in contrast to only four of ten treated with rFel d 1. Compared to rFel d 1, the hypoallergen showed a tendency of reduced SPT reactivity.

CONCLUSION:

  The rFel d 1 (DTE III) hypoallergen might be a promising candidate for application in immunotherapy of cat allergy with improved safety and efficacy.

• Authors: T Saarne, T Neimert-Andersson, H Grönlund, M Jutel, G Gafvelin, M van Hage
• Journal: Allergy (Allergy) Vol. 66 Issue 2 Pg. 255-63 (Feb 2011) ISSN: 1398-9995 [Electronic] Denmark
• PMID: 20804464 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2010 John Wiley & Sons A/S.

Chemical References

• Glycoproteins
• Immunoglobulin G
• Recombinant Proteins
• Immunoglobulin E
• Fel d 1 protein, Felis domesticus

Topics

• Animals
• Antigen-Antibody Reactions (drug effects)
• Case-Control Studies
• Cats
• Disease Models, Animal
• Glycoproteins (administration & dosage, therapeutic use)
• Humans
• Hypersensitivity (drug therapy)
• Immunoglobulin E
• Immunoglobulin G (biosynthesis, pharmacology)
• Immunotherapy (methods)
• Mice
• Recombinant Proteins
• Treatment Outcome